Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Phase II trial to study the effectiveness of oxaliplatin in treating patients who have relapsed or refractory non-Hodgkin's lymphoma. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Cancer Institute (NCI)
• Treatments: Oxaliplatin

Criteria

Inclusion Criteria:

• Histologically or cytologically confirmed recurrent or refractory non-Hodgkin's lymphoma (NHL) of any histologic subtype

• Indolent

• Follicular small cleaved cell

• Follicular mixed cell

• Small lymphocytic

• Mucosa-associated lymphoid tissue (MALT)

• Monocytoid B-cell

• Waldenstrom's macroglobulinemia

• Aggressive

• Follicular large cell

• Diffuse large cell

• Immunoblastic

• Mantle cell

• Ki-1+ NHL

• Peripheral T-cell

• Angiocentric and angioimmunoblastic

• Transformed lymphoma

• Bidimensionally measurable disease

• No more than 3 prior treatment regimens as follows:

• Primary radiotherapy is 1 regimen

• Combined therapy with radiotherapy and chemotherapy is 1 regimen

• Alternating therapy is 1 regimen

• No known brain metastases

• Performance status - ECOG 0-2

• Performance status - Karnofsky 50-100%

• WBC count at least 3,000/mm^3

• Absolute neutrophil count at least 1,500/mm^3

• Platelet count at least 100,000/mm^3

• Bilirubin normal

• SGOT/SGPT no greater than 2.5 times upper limit of normal

• Creatinine normal

• Creatinine clearance at least 60 mL/min

• No symptomatic congestive heart failure

• No unstable angina pectoris

• No cardiac arrhythmia

• No neuropathy greater than grade 1

• No history of allergy to platinum compounds or antiemetics

• No uncontrolled illness

• No active infection

• Not pregnant or nursing

• Fertile patients must use effective contraception

• No concurrent colony-stimulating factors during first course of therapy

• At least 4 weeks since prior chemotherapy

• At least 4 weeks since prior radiotherapy

• No other concurrent investigational drugs

• No concurrent antiretroviral therapy for HIV-positive patients